Proteomics in Acute Myelogenous Leukaemia (AML): Methodological Strategies and Identification of Protein Targets for Novel Antileukaemic Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|6|6|631-646

ISSN： 1389-4501

Source： Current Drug Targets, Vol.6, Iss.6, 2005-09, pp. : 631-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteomic Strategies for Individualizing Therapy of Acute MyeloidLeukemia (AML)

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 3, 2006-06 ,pp. : 159-170

Bentham Science Publishers

Access to resources Recommend Favorite

Src kinases as targets for Bcell acute lymphoblastic leukaemia therapy

By Li Shaoguang  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 2, 2005-04 ,pp. : 329-341

Informa Healthcare

Access to resources Recommend Favorite

Recent advances in targeted therapy of human myelogenous leukaemia

By Paz Keren   Zhu Zhenping  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1147-1163

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies

By  

Current Cancer Drug Targets, Vol. 5, Iss. 4, 2005-06 ,pp. : 229-248

Bentham Science Publishers

Access to resources Recommend Favorite

Colony-Stimulating Factors in the Treatment of Older Patients with Acute Myelogenous Leukaemia

By Bolam S.   Hamblin T.  

Drugs & Aging, Vol. 15, Iss. 6, 1999-12 ,pp. : 451-460

Adis International

Access to resources Recommend Favorite